| Atezolizumab plus chemotherapy for first-line treatment of nonsquamous NSCLC: results from the randomized phase 3 IMpower132 trial M Nishio, F Barlesi, H West, S Ball, R Bordoni, M Cobo, PD Longeras, ... Journal of thoracic oncology 16 (4), 653-664, 2021 | 308 | 2021 |
| Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer TG Oliver, KL Mercer, LC Sayles, JR Burke, D Mendus, KS Lovejoy, ... Genes & development 24 (8), 837-852, 2010 | 242 | 2010 |
| OA05. 07 IMpower132: PFS and safety results with 1L atezolizumab+ carboplatin/cisplatin+ pemetrexed in stage IV non-squamous NSCLC V Papadimitrakopoulou, M Cobo, R Bordoni, P Dubray-Longeras, ... Journal of Thoracic Oncology 13 (10), S332-S333, 2018 | 167 | 2018 |
| IMpower132: Efficacy of atezolizumab (atezo)+ carboplatin (carbo)/cisplatin (cis)+ pemetrexed (pem) as 1L treatment in key subgroups with stage IV non-squamous non-small cell … F Barlesi, M Nishio, M Cobo, N Steele, V Paramonov, B Parente, R Dear, ... Annals of Oncology 29, viii743-viii744, 2018 | 59 | 2018 |
| Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L+ NSCLC DR Gandara, M Reck, S Morris, A Cardona, D Mendus, M Ballinger, ... Annals of Oncology 29, x39, 2018 | 31 | 2018 |
| Thrombospondins 1 and 2 are important for afferent synapse formation and function in the inner ear D Mendus, S Sundaresan, N Grillet, F Wangsawihardja, R Leu, U Müller, ... European Journal of Neuroscience 39 (8), 1256-1267, 2014 | 30 | 2014 |
| LBA2 Updated analysis and patient-reported outcomes (PROs) from CITYSCAPE: A randomised, double-blind, phase II study of the anti-TIGIT antibody tiragolumab+ atezolizumab (TA … BC Cho, D Rodriguez-Abreu, M Hussein, M Cobo, A Patel, N Secen, ... Annals of Oncology 32, S1428, 2021 | 24 | 2021 |
| Fast progression in non–small cell lung cancer: Results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel D Gandara, M Reck, D Moro-Sibilot, J Mazieres, S Gadgeel, S Morris, ... Journal for immunotherapy of cancer 9 (3), 2021 | 18 | 2021 |
| Increased sensitivity to kindling in mice lacking TSP1 D Mendus, EK Rankin-Gee, M Mustapha, BE Porter Neuroscience 305, 302-308, 2015 | 14 | 2015 |
| LBA-5 Phase Ib study of the anti-TIGIT antibody tiragolumab in combination with atezolizumab in patients with metastatic esophageal cancer Z Wainberg, I Matos, J Delord, P Cassier, M Gil-Martin, T Kim, P LoRusso, ... Annals of Oncology 32, S227-S228, 2021 | 13 | 2021 |
| A lack of immune system genes causes loss in high frequency hearing but does not disrupt cochlear synapse maturation in mice MA Calton, D Lee, S Sundaresan, D Mendus, R Leu, F Wangsawihardja, ... PLoS One 9 (5), e94549, 2014 | 13 | 2014 |
| Anti-TIGIT antibody Tiragolumab alone or with Atezolizumab in patients with advanced solid tumors: a phase 1a/1b nonrandomized controlled trial TW Kim, PL Bedard, P LoRusso, MS Gordon, J Bendell, DY Oh, MJ Ahn, ... JAMA oncology 9 (11), 1574-1582, 2023 | 10 | 2023 |
| 375O final efficacy results from IMpower132: first-line atezolizumab+ chemotherapy in patients with stage IV non-squamous NSCLC M Nishio, F Barlesi, S Ball, R Bordoni, M Cobo, P Dubray-Longeras, ... Annals of Oncology 31, S1386-S1387, 2020 | 9 | 2020 |
| Diphenhydramine increases the therapeutic window for platinum drugs by simultaneously sensitizing tumor cells and protecting normal cells M Melnikova, US Wauer, D Mendus, RA Hilger, TG Oliver, K Mercer, ... Molecular oncology 14 (4), 686-703, 2020 | 7 | 2020 |
| IMpower132: efficacy of atezolizumab+ carboplatin/cisplatin+ pemetrexed as 1L treatment in key subgroups with stage IV non-squamous NSCLC F Barlesi, M Nishio, M Cobo, N Steele, V Paramonov, B Parente Ann. Oncol 29, 2018 | 5 | 2018 |
| Pharmacokinetics (PK) of Tiragolumab in First‐in‐Human Study in Patients with Mixed Solid Tumors (GO30103) E Garralda, DY Oh, A Italiano, PL Bedard, JP Delord, E Calvo, P LoRusso, ... The Journal of Clinical Pharmacology 64 (5), 544-554, 2024 | 2 | 2024 |
| Cisplatin-induced DNA damage in normal and malignant cells: Mechanisms of drug resistance and side effects and strategies for their prevention D Mendus PhD Thesis]. https://duepublico. uni-duisburgessen. de/servlets …, 2010 | 2 | 2010 |
| Methods for treatment of cancer with an anti-tigit antagonist antibody LAI Catherine, LAU Janet, AJ Lee, S Li, YG Lin-liu, CJ Matheny, ... | | 2022 |
| Methods for treatment of cancer with an anti-tigit antagonist antibody LAI Catherine, LAU Janet, AJ LEE, S Li, YG LIN-LIU, CJ MATHENY, ... | | 2021 |
| Simulating RTOG 0617 using Genomic Adjusted Radiation Dose: Comparing Apples With Oranges Response M Nishio, D Mendus, L Wang, MA Socinski JOURNAL OF THORACIC ONCOLOGY 16 (5), E30-E31, 2021 | | 2021 |
